Actinium Pharmaceuticals, Inc. (ATNM)

1.780.01 (-0.56%)

Actinium Pharmaceuticals, Inc. (ATNM) stock comprehensive Financial Growth Analysis including revenue, gross profit, operating profit, net profit, EPS, and other financial metrics. Compare financial growth against peers/competitors, industry and sector standards.

High Bankruptcy RiskBelow Average ESGFair ValuationLow ProfitabilityAdequate Financial HealthInefficient OperationsModerate GrowthLow QualityAdequate Dividend ProfileIndustry Rank: 20.71%Sector Rank: 20.11%

AMEX - Healthcare - Biotechnology | Market Cap: 55.53M | Next Earnings Date: 13 Nov 2025

Day's Range

1.75 - 1.81

52-Week Range

1.03 - 2.41

Volume

122.5K / 296.7K (Avg.)

P/E Ratio | EPS

-1.36 | -1.31

Trending:

ATNM Financial Growth Analysis

Compare against a Competitor

None AGEN AVXL RVPH AXSM TRAW

Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.

Revenue Growth

No Data

No Data available this quarter, please select a different quarter.

Gross Profit Growth

No Data

No Data available this quarter, please select a different quarter.

EBIT Growth

-184.01%

Increased from previous period

Negative EBIT growth while Healthcare median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.

Operating Income Growth

-178.81%

Decreased from previous period

Negative operating income growth while Healthcare median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.

Net Income Growth

-184.01%

Increased from previous period

Negative net income growth while Healthcare median is 0.00%. Seth Klarman would investigate factors dragging net income down.

EPS Growth

-184.12%

Increased from previous period

Negative EPS growth while Healthcare median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.

Diluted EPS Growth

-184.12%

Increased from previous period

Negative diluted EPS growth while Healthcare median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.

Share Count Growth (Basic)

No Data

No Data available this quarter, please select a different quarter.

Share Count Growth (Diluted)

No Data

No Data available this quarter, please select a different quarter.

Dividend per Share Growth

No Data

No Data available this quarter, please select a different quarter.

Operating Cash Flow Growth

-85.28%

Decreased from previous period

Negative OCF growth while Healthcare median is -7.20%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.

Free Cash Flow Growth

-84.23%

Decreased from previous period

Negative FCF growth while Healthcare median is -5.78%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.

10-Year Revenue Growth per Share (CAGR)

No Data

No Data available this quarter, please select a different quarter.

5-Year Revenue Growth per Share (CAGR)

No Data

No Data available this quarter, please select a different quarter.

3-Year Revenue Growth per Share (CAGR)

No Data

No Data available this quarter, please select a different quarter.

10-Year Operating Cash Flow Growth per Share

-94305.07%

Decreased from previous period

Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.

5-Year Operating Cash Flow Growth per Share

-10645.39%

Increased from previous period

Negative 5Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.

3-Year Operating Cash Flow Growth per Share

-26633.07%

Decreased from previous period

Negative 3Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.

10-Year Net Income Growth per Share

-5092186.63%

Decreased from previous period

Negative 10Y net income/share CAGR vs. Healthcare median of 14.97%. Seth Klarman might see a fundamental problem if peers maintain growth.

5-Year Net Income Growth per Share

-138877.64%

Decreased from previous period

Negative 5Y CAGR while Healthcare median is 11.28%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.

3-Year Net Income Growth per Share

-184266.59%

Decreased from previous period

Negative 3Y CAGR while Healthcare median is 0.00%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.

10-Year Shareholders’ Equity Growth per Share

-96972.06%

Decreased from previous period

Negative 10Y equity/share growth while Healthcare median is 0.00%. Seth Klarman would see a firm-specific weakness if peers still expand equity.

5-Year Shareholders’ Equity Growth per Share

-7412.05%

Decreased from previous period

Negative 5Y equity/share growth while Healthcare median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.

3-Year Shareholders’ Equity Growth per Share

-5938.31%

Decreased from previous period

Negative 3Y equity/share growth while Healthcare median is 0.06%. Seth Klarman sees a short-term weakness if peers still expand net worth.

10-Year Dividend per Share Growth (CAGR)

No Data

No Data available this quarter, please select a different quarter.

5-Year Dividend per Share Growth (CAGR)

No Data

No Data available this quarter, please select a different quarter.

3-Year Dividend per Share Growth (CAGR)

No Data

No Data available this quarter, please select a different quarter.

Receivables Growth

No Data

No Data available this quarter, please select a different quarter.

Inventory Growth

No Data

No Data available this quarter, please select a different quarter.

Asset Growth

13.78%

Decreased from previous period

Asset growth of 13.78% while Healthcare median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.

Book Value per Share Growth

-763.59%

Decreased from previous period

Negative BV/share change while Healthcare median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.

Debt Growth

-40.14%

Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.

R&D Expense Growth

738.04%

Increased from previous period

R&D growth of 738.04% while Healthcare median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.

SG&A Expenses Growth

40.95%

Decreased from previous period

SG&A growth far above Healthcare median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.

+ Add New Metric (Coming Soon)

Add more metric or remove existing ones, customize as per your preference, feature coming soon!

Select Chart Metric:

ATNM Financial Growth Analysis

Compare against a Competitor

None AGEN AVXL RVPH AXSM TRAW

Revenue Growth

No Data

No Data available this quarter, please select a different quarter.

Gross Profit Growth

No Data

No Data available this quarter, please select a different quarter.

EBIT Growth

-184.01%

Increased from previous period

Negative EBIT growth while Healthcare median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.

Operating Income Growth

-178.81%

Decreased from previous period

Negative operating income growth while Healthcare median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.

Net Income Growth

-184.01%

Increased from previous period

Negative net income growth while Healthcare median is 0.00%. Seth Klarman would investigate factors dragging net income down.

EPS Growth

-184.12%

Increased from previous period

Negative EPS growth while Healthcare median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.

Diluted EPS Growth

-184.12%

Increased from previous period

Negative diluted EPS growth while Healthcare median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.

Share Count Growth (Basic)

No Data

No Data available this quarter, please select a different quarter.

Share Count Growth (Diluted)

No Data

No Data available this quarter, please select a different quarter.

Dividend per Share Growth

No Data

No Data available this quarter, please select a different quarter.

Operating Cash Flow Growth

-85.28%

Decreased from previous period

Negative OCF growth while Healthcare median is -7.20%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.

Free Cash Flow Growth

-84.23%

Decreased from previous period

Negative FCF growth while Healthcare median is -5.78%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.

10-Year Revenue Growth per Share (CAGR)

No Data

No Data available this quarter, please select a different quarter.

5-Year Revenue Growth per Share (CAGR)

No Data

No Data available this quarter, please select a different quarter.

3-Year Revenue Growth per Share (CAGR)

No Data

No Data available this quarter, please select a different quarter.

10-Year Operating Cash Flow Growth per Share

-94305.07%

Decreased from previous period

Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.

5-Year Operating Cash Flow Growth per Share

-10645.39%

Increased from previous period

Negative 5Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.

3-Year Operating Cash Flow Growth per Share

-26633.07%

Decreased from previous period

Negative 3Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.

10-Year Net Income Growth per Share

-5092186.63%

Decreased from previous period

Negative 10Y net income/share CAGR vs. Healthcare median of 14.97%. Seth Klarman might see a fundamental problem if peers maintain growth.

5-Year Net Income Growth per Share

-138877.64%

Decreased from previous period

Negative 5Y CAGR while Healthcare median is 11.28%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.

3-Year Net Income Growth per Share

-184266.59%

Decreased from previous period

Negative 3Y CAGR while Healthcare median is 0.00%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.

10-Year Shareholders’ Equity Growth per Share

-96972.06%

Decreased from previous period

Negative 10Y equity/share growth while Healthcare median is 0.00%. Seth Klarman would see a firm-specific weakness if peers still expand equity.

5-Year Shareholders’ Equity Growth per Share

-7412.05%

Decreased from previous period

Negative 5Y equity/share growth while Healthcare median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.

3-Year Shareholders’ Equity Growth per Share

-5938.31%

Decreased from previous period

Negative 3Y equity/share growth while Healthcare median is 0.06%. Seth Klarman sees a short-term weakness if peers still expand net worth.

10-Year Dividend per Share Growth (CAGR)

No Data

No Data available this quarter, please select a different quarter.

5-Year Dividend per Share Growth (CAGR)

No Data

No Data available this quarter, please select a different quarter.

3-Year Dividend per Share Growth (CAGR)

No Data

No Data available this quarter, please select a different quarter.

Receivables Growth

No Data

No Data available this quarter, please select a different quarter.

Inventory Growth

No Data

No Data available this quarter, please select a different quarter.

Asset Growth

13.78%

Decreased from previous period

Asset growth of 13.78% while Healthcare median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.

Book Value per Share Growth

-763.59%

Decreased from previous period

Negative BV/share change while Healthcare median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.

Debt Growth

-40.14%

Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.

R&D Expense Growth

738.04%

Increased from previous period

R&D growth of 738.04% while Healthcare median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.

SG&A Expenses Growth

40.95%

Decreased from previous period

SG&A growth far above Healthcare median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.

+ Add New Metric (Coming Soon)

Add more metric or remove existing ones, customize as per your preference, feature coming soon!

Select Chart Metric: